Feiba



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 18.0%
Acquired Haemophilia 13.4%
Factor Viii Inhibition 13.2%
Haemophilia 8.8%
Haemostasis 8.6%
Factor Viii Deficiency 6.6%
Prophylaxis 4.6%
Haemorrhage 3.4%
Pain 3.2%
Off Label Use 2.8%
Post Procedural Haemorrhage 2.6%
Tooth Abscess 2.0%
Drug Use For Unknown Indication 1.8%
Haemorrhage Prophylaxis 1.8%
Premedication 1.8%
Diabetes Mellitus 1.6%
Hypertension 1.6%
Insomnia 1.6%
Anaemia 1.4%
Haemarthrosis 1.4%
Hepatitis B Surface Antibody Positive 12.8%
Drug Ineffective 10.4%
Renal Failure 9.6%
Factor Viii Inhibition 7.2%
Blood Fibrinogen Decreased 5.6%
Haemorrhage 5.6%
Haemorrhagic Stroke 5.6%
Disseminated Intravascular Coagulation 4.8%
Hepatitis B Antibody Positive 4.8%
Haemarthrosis 4.0%
Pneumonia 4.0%
Anaphylactic Shock 3.2%
Death 3.2%
Fibrin D Dimer Increased 3.2%
Ischaemic Stroke 3.2%
Vomiting 3.2%
Cerebrovascular Accident 2.4%
Deep Vein Thrombosis 2.4%
Drug Effect Decreased 2.4%
Post Procedural Haemorrhage 2.4%
Secondary
Factor Viii Inhibition 46.4%
Prophylaxis 19.3%
Product Used For Unknown Indication 5.9%
Acquired Haemophilia 5.8%
Factor Viii Deficiency 4.5%
Pain 2.2%
Haemophilia 1.8%
Haemostasis 1.8%
Premedication 1.7%
Haemorrhage 1.3%
Haematoma 1.3%
Tooth Abscess 1.3%
Depression 1.1%
Haemarthrosis 1.1%
Hypertension 0.9%
Anaemia 0.9%
Infection Prophylaxis 0.7%
Muscle Haemorrhage 0.7%
Agitation 0.6%
Constipation 0.6%
Hepatitis B Surface Antibody Positive 76.5%
Hepatitis B Surface Antigen Positive 7.0%
Haemarthrosis 4.2%
Blood Fibrinogen Decreased 2.5%
Hepatitis B Antibody Positive 1.7%
Oedema Peripheral 1.3%
Pneumonia 1.0%
Drug Effect Decreased 0.8%
Enterobacter Infection 0.8%
Drug Ineffective 0.7%
Thrombophlebitis Superficial 0.7%
Renal Failure 0.4%
Leukocytosis 0.4%
Factor Viii Inhibition 0.4%
Ileus Paralytic 0.4%
Haemorrhage 0.3%
Thrombosis 0.3%
Disseminated Intravascular Coagulation 0.2%
Vomiting 0.2%
Arthralgia 0.2%
Concomitant
Hiv Infection 22.9%
Acquired Haemophilia 10.2%
Drug Use For Unknown Indication 9.3%
Haemophilia A With Anti Factor Viii 8.5%
Immunosuppressant Drug Therapy 7.6%
Haemostasis 5.9%
Factor Viii Deficiency 4.2%
Haemorrhage 4.2%
Retroperitoneal Haematoma 3.4%
Diarrhoea 2.5%
Haemarthrosis 2.5%
Haemophilia 2.5%
Hepatitis C 2.5%
Insomnia 2.5%
Muscle Haemorrhage 2.5%
Adverse Event 1.7%
Bipolar Disorder 1.7%
Cerebral Haemorrhage 1.7%
Coagulopathy 1.7%
Factor Viii Inhibition 1.7%
Multi-organ Failure 11.9%
Pyrexia 11.9%
Death 7.1%
Osteonecrosis 7.1%
Thrombosis 7.1%
Cerebral Haemorrhage 4.8%
Drug Ineffective 4.8%
Haematoma 4.8%
Muscle Haemorrhage 4.8%
Renal Haemorrhage 4.8%
Sudden Death 4.8%
Tachycardia 4.8%
Transmission Of An Infectious Agent Via A Medicinal Product 4.8%
Abdominal Pain 2.4%
Agranulocytosis 2.4%
Cerebellar Haemorrhage 2.4%
Cholelithiasis 2.4%
Face Injury 2.4%
Factor Viii Inhibition 2.4%
Hypersensitivity 2.4%